A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

• Status: Completed
• Trial end date: 2017-08-23

Summary

The purpose of this study is to determine brain penetration of single oral doses of TAK-041 and its effects on amphetamine-induced dopamine release in the Central Nervous System (CNS).

• Phase: Phase 1

Details

• Lead Sponsor: Neurocrine Biosciences; Takeda
• Collaborator: Takeda
• Treatments: Amphetamine; Dopamine; Naxagolide